当前位置:首页 >英文主页 >中英对照 > 中译版报告详情

艾昆纬(IQVIA):2025构建激励性参与生态系统:肥胖症临床研究成功之道白皮书(中译版)(15页).pdf

上传人: 1****1 编号:1036428 2026-01-13 15页 3.93MB

下载:

1、White PaperCreating a Motivating Engagement Ecosystem:Achieving Success in Obesity ResearchDEBRA GERLACH,Director,Patient Recruitment Strategy Clinical Operations,IQVIASTEPHANIE GALARZA,Associate Director,Patient Recruitment Strategy Clinical Operations,IQVIAIncorporating the patient voice and lived

2、 experience into the trial journeyTable of contentsUnderstanding the emotional impact of obesity 1Insight-driven strategies for a supportive treatment experience 3Customizing engagement for diverse patient populations 4Elevating the patient voice in trial content 6Designing engagement strategy aroun

3、d the patients lived experience 6Personalizing nutritional counseling with registered dietitians 7What sites need:Strategies and tools for optimal support 8Beyond Borders:Leveraging site intelligence for regional customization 9Looking ahead:Opportunities and challenges in obesity research 10Referen

4、ces 11About the authors 12 |1Understanding the emotional impact of obesityThe development,widespread adoption,and intense public curiosity of GLP-1 receptor agonists have reshaped global perceptions of obesity and transformed therapeutic approaches.These innovations have sparked robust dialogue acro

5、ss clinical,cultural,and societal domains,lending legitimacy to the recognition of obesity as a treatable medical condition.The surge of more than 124 investigational molecules in the pipeline presents a significant opportunity to improve the health of millions of people struggling with obesity worl

6、dwide.This growth will intensify competition among sponsors,CROs,and sites for participant recruitment and retention.As more approved treatment options become available,finding treatment-nave patients will become increasingly challenging.Additionally,since many of these pipeline candidates target pa

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **肥胖研究的挑战与机遇**:GLP-1受体激动剂推动肥胖被视为可治疗的医疗条件,但124个在研分子加剧患者招募竞争,且需针对合并症细化入组标准,美国《通胀削减法案》要求证明治疗价值。 2. **患者核心痛点**:69%患者感到羞耻,52%担心无法陪伴家人,49%担忧额外医疗成本,32%因体重遭歧视或感到孤独,凸显需关注其情绪与社会负担。 3. **患者驱动的参与策略**: - **关键动机**:改善健康(46%)、减重(34%)、个性化营养指导(44%); - **主要障碍**:副作用担忧(42%)、缺乏明显改善(33%)、医护不尊重(33%)。 4. **成功要素**: - **个性化支持**:注册营养师(93%站点认为有效)、灵活数字工具、文化适应性内容; - **区域定制**:美国侧重数字招募与先进疗法,欧洲需协调本地医疗体系; - **患者声音融入**:通过行为科学创建患者画像,提升试验包容性与动机。
肥胖患者为何焦虑? 如何提升试验参与率? 个性化支持有多重要?
客服
商务合作
小程序
服务号
折叠